Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed hepatocellular carcinoma (HCC) or intrahepatic
cholangiocarcinoma (ICC)

- Peripheral, cholangiolar, or cholangiocellular types

- Mixed HCC/ICC disease allowed

- Unresectable disease

- Less than 70% liver involvement

- Radiographically bidimensionally measurable disease, defined as lesion ≥ 2 cm in the
greatest diameter

- May have failed prior systemic chemotherapy or ablative therapy

- No radiographic evidence of esophageal varices

- No history of variceal hemorrhage

- No occlusion of the main portal vein or the right and left portal branches

- No clinical ascites

- Patients ineligible for first-line MSKCC protocols for HCC are eligible for this
study provided there is no clinical or radiographic evidence of extrahepatic disease

- No metastatic disease, including CNS metastases

PATIENT CHARACTERISTICS:

- Life expectancy ≥ 12 weeks

- Karnofsky performance status 60-100%

- Considered a candidate for general anesthesia and hepatic artery pump placement

- Platelet count > 100,000/mm³

- Albumin > 2.5 g/dL

- Bilirubin < 1.8 mg/dL

- WBC > 3,500/mm³

- PTT < 1.5 times upper limit of normal

- INR < 1.5 OR in-range INR (usually 2.0-3.0) for patients on a stable dose of
therapeutic warfarin

- Urine protein < 1+ by dipstick or urine analysis OR urine protein:creatinine ratio <
1.0

- If proteinuria ≥ 2+ at baseline, patient must have < 1 g protein/24-hour
collection

- No concurrent disease or illness that would preclude study participation, including
any of the following:

- Hepatic encephalopathy

- Sclerosing cholangitis

- Gilbert's disease

- Active infection

- No known CNS disease

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to bevacizumab

- No psychiatric illness or social situation that would preclude study compliance

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 6 months

- No serious or nonhealing active wound, ulcer, or bone fracture

- No bleeding diathesis or coagulopathy

- No clinically significant cardiovascular disease, including any of the following:

- Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg
or diastolic BP > 100 mm Hg on antihypertensive medications

- New York Heart Association class II-IV congestive heart failure

- Vascular disease (e.g., aortic aneurysm, aortic dissection)

- Myocardial infarction within the past 6 months

- Symptomatic peripheral vascular disease

- Unstable angina within the past 6 months

- History of hypertensive crisis

- Transient ischemic attack

- Stroke

- No other concurrent malignancy except localized basal cell or squamous cell skin
cancer

- Chronic hepatitis and/or cirrhosis allowed provided it is Child-Pugh class A disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 4 weeks since prior and no other concurrent experimental therapy except on
a Genentech-sponsored bevacizumab cancer study

- More than 4 weeks since prior major surgical procedure or open biopsy

- More than 1 week since prior minor surgical procedure (e.g., core biopsy), excluding
placement of a vascular access device

- No prior external-beam radiation therapy to the liver

- No prior floxuridine

- No chronic daily treatment with nonsteroidal anti-inflammatory medications known to
inhibit platelet function

- No chronic daily treatment with aspirin (> 325 mg/day)

- No concurrent or recent use of a thrombolytic agent

- No concurrent major surgery